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Cellular Target of a Rhodium Metalloinsertor is the DNA Base Pair 
Mismatch 
Kelsey M. Boyle, Adela Nano, Catherine Day, and Jacqueline K. Barton* 
Abstract: Defects in DNA mismatch repair (MMR) are commonly 
found in various cancers, especially in colorectal cancers. Despite the 
high prevalence of MMR-deficient cancers, mismatch-targeted 
therapeutics are limited and diagnostic tools are indirect. Here, we 
examine the cytotoxic properties of a rhodium metalloinsertor, 
[Rh(phen)(chrysi)(PPO)]2+ (RhPPO) in 27 diverse colorectal cancer 
cell lines. Despite the low frequency of genomic mismatches and the 
non-covalent nature of the RhPPO-DNA lesion, RhPPO is on average 
5 times more potent than cisplatin. Importantly, the biological target 
and profile for RhPPO differs from that of cisplatin. A fluorescent 
metalloinsertor, RhCy3, was used to demonstrate that the cellular 
target of RhPPO is the DNA mismatch. RhCy3 represents a direct 
probe for MMR-deficiency and correlates directly with the cytotoxicity 
of RhPPO across different cell lines. Overall, our studies clearly 
indicate that RhPPO and RhCy3 are promising anticancer and 
diagnostic probes for MMR-deficient cancers, respectively.  
 
 
Deficiencies in cellular mismatch repair (MMR) machinery 
are a hallmark of 14% of colorectal cancer cases and up to 20% 
of all solid tumors.[1,2] Cells with MMR-deficiencies (MMR−) cannot 
repair DNA mismatches or insertions/deletions (indels), leading to 
a relative abundance of these lesions in these cells. Mismatches 
could thus serve as a unique druggable target that has yet to be 
utilized in a clinical setting. Furthermore, these lesions could 
serve as a target for direct detection and diagnosis of MMR 
deficiencies in tumors, something that is commonly measured 
indirectly through tests of mutational frequency in microsatellite 
regions instead of number of mismatches.[2b] Such a diagnostic 
would further support the promise of a mismatch- and indel-
targeted therapeutic agent. Our group and others have addressed 
this need through the development of mismatch-targeted small 
molecules.[3] Specifically, our group has developed a unique 
family of metal complexes, called rhodium metalloinsertors, that 
can selectively target thermodynamically destabilized regions of 
DNA, such as base pair mismatches (Figure 1), small indels, and 
abasic sites, making the metal complexes an ideal candidate for 
targeting and detecting the DNA lesions found in MMR-deficient 
tumors.[4–7] 
Rhodium metalloinsertors have been rigorously studied in 
several pairs of matched cancer cell lines which differ primarily in 
the presence or absence of functioning MMR machinery.[8,9] In 
every matched pairing, metalloinsertors are significantly more 
cytotoxic towards the MMR− cell line compared to their MMR-
proficient (MMR+) counterpart (a feature referred to as selectivity). 
These results demonstrate that rhodium metalloinsertors can 
target MMR deficiencies in cells, however they do not prove the 
specific cellular target of metalloinsertors to be DNA mismatches. 
Furthermore, these cell pairings are not reflective of the diversity 
of clinical colorectal cancer (CRC) cases; in reality, the 
differences between tumors in two different patients or healthy 
and cancerous tissues in a single patient will be far greater than 
just the presence or absence of a single MMR protein.[10,11] 
 
 
Figure 1. The binding and structure of a metalloinsertor and cisplatin. As 
observed crystallographically in previous studies, a classic metalloinsertor binds 
selectively to a mismatch in DNA (top left, PDB 3GSK), while cisplatin binds to 
a d(GpG) site in DNA (top right, PDB 1AIO). The structures of RhPPO (middle 
left), cisplatin (middle right), and RhCy3 (bottom). 
 
To understand more fully the potential clinical applicability of 
rhodium metalloinsertors, we examined our most potent and 
selective metalloinsertor, [Rh(phen)(chrysi)(PPO)]Cl2 (RhPPO, 
Figure 1), across 27 CRC cell lines (Table S1).[12,13] These cell 
lines represent a diverse set of tumors, spanning the four 
subtypes of CRC and both MMR− and MMR+ phenotypes.[14,15] 
The toxicities of RhPPO, which selectively targets MMR 
deficiencies, and the non-selective FDA-approved 
chemotherapeutic cisplatin, which covalently binds the abundant 
d(GpG) motifs present in all DNA (Figure 1), were assessed in 
this cell line panel using a luciferase-based luminescence assay 
which measures ATP from living cells. Dose-response curves and 
corresponding IC50 values (50% inhibitory concentration) were 
determined for each therapeutic and are shown in Figure 2 and 
Table S2. The IC50 values of RhPPO in different cell lines span 
nearly three orders of magnitude, ranging from 63 ± 3 nM to 18 ± 
3 μM. Despite the low number of genomic mismatches, RhPPO 
is more potent than cisplatin in nearly every cell line, with the IC50 
values of RhPPO being on average 5 times lower than those of 
cisplatin (2.9 μM vs. 13.2 μM, respectively). This result is 
remarkable considering that DNA mismatches are significantly 
less abundant than d(GpG) sites and metalloinsertors interact 
only through non-covalent stacking with these mismatches. The 
potency of a therapeutic in cell culture has long been considered 
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a key predictor of its clinical success; potent therapeutics have 
the potential for low dosing conditions, 
 
Figure 2. Cytotoxicity of RhPPO and cisplatin in 27 colorectal cancer cell lines. 
Dose response curves of RhPPO and cisplatin in CRC cell lines (top). Dose 
response curves of RhPPO in MMR− and MMR+ CRC cell lines (middle top). 
Direct IC50 comparison of RhPPO and cisplatin in 27 CRC cell lines (middle 
bottom) and boxplot representation, with an average IC50 for RhPPO of 3.02 
μM and a median of 1.34 μM, and an average IC50 for cisplatin of 13.89 μM 
and a median of 11.62 μM (bottom).  
 
low off-target effects, and minimal solubility issues.[16,17] Therefore, 
the high potency of RhPPO highlights its great therapeutic 
potential. Furthermore, in the cell lines least sensitive to cisplatin 
(Colo205, HT29, and WiDr), RhPPO is over 100 times more 
potent than cisplatin (Table S2), suggesting it could be a 
particularly useful therapeutic for treatment of clinically 
challenging cisplatin-resistant tumors. 
When considering MMR status, a wide range of sensitivities 
is observed for both MMR− and MMR+ cell lines (Figure 2). The 
sensitivities of some cell lines are contrary to what we expected 
based solely on MMR status; some MMR− cell lines (DLD-1, 
HCT15, and CW2) show minimal sensitivity to RhPPO, whereas 
some MMR+ cell lines (HT29, WiDr, Ls123, and Colo205) show 
high sensitivity to RhPPO. Overall RhPPO shows moderate 
selectivity towards the MMR− cell lines (average IC50 of 2.5 μM) 
compared to MMR+ cell lines (average IC50 of 3.0 μM), and the 
selectivity increases further when looking only at cell lines with 
deficiencies in MLH1 or MSH2, the two most essential MMR 
proteins (average IC50 of 2.1 μM, Figure S1). These results are 
promising and follow the expected trend, however they are not as 
significant as anticipated (Figure S1). The range observed for 
both MMR− and MMR+ cell lines can be rationalized; unlike in 
matched cell lines, cell lines in this panel differ in mutations and 
regulation of many proteins.[10,11] Accordingly, there are several 
factors that could obscure the strong MMR− selectivity we 
expected based on our hypothesis. We investigated two such 
factors that seemed likely to influence metalloinsertor toxicity: 
cellular uptake and the number of lesions in genomic DNA that 
can be targeted by metalloinsertors.  
Cell lines can exhibit different uptake and efflux properties 
towards small molecule therapeutic, therefore differences in 
uptake between cell lines may explain the wide cytotoxicity range 
of RhPPO.[18,19] We measured the whole cell uptake of RhPPO 
after 24 hours in various cell lines by ICP-MS to determine if the 
whole cell uptake of RhPPO correlated with cytotoxicity (Figure 3 
and Figure S2). A significant correlation (Pearson’s r = -0.63, p < 
0.01) was observed between increasing RhPPO uptake and 
decreasing IC50. Furthermore, several of the results contrary to 
our hypothesis (i.e. high IC50 in MMR− cells, low IC50 in MMR+ 
cells) are clarified by this assay; the three MMR− cell lines least 
sensitive to RhPPO (DLD-1, HT29, CW2) show the lowest cellular 
uptake and two of the most sensitive MMR+ cell lines (Ls123 and 
Colo205) exhibit the highest cellular uptakes. For these cell lines, 
high or low cellular uptake of RhPPO likely obscures the 
selectivity that would normally be observed on the basis of MMR 
status alone. While this correlation between uptake and 
cytotoxicity is intuitive, it is of note that there are few reported 
studies correlating cellular uptake and cytotoxicity of a small 
molecule therapeutic across different cell lines.[20] More 
commonly, reports examine the correlation of cellular uptake and 
cytotoxicity of different therapeutics in a single cell line or look only 
at a relatively small number of cell lines.[21] Therefore, our results 
comparing cytotoxicity and cellular uptake suggest that uptake 
may often play a non-negligible role in the cytotoxicity differences 
of a small molecule therapeutic between cell lines.  
While a correlation between cytotoxicity and uptake is 
expected for any small molecule therapeutic, a correlation 
between cytotoxicity and DNA binding would only be expected if 
DNA were the relevant biological target of the therapeutic being 
studied. As discussed previously, inactivation of MMR proteins 
confers the cells with an increased level of uncorrected 
mismatches and indels that propagate into mutations upon 
replication.[3] The number of these lesions in the genome can 
fluctuate between cell lines, for instance mutations (an indirect 
measure of mismatches and indels) occur at different rates in cell 
lines deficient in different MMR proteins.[22] The number of these 
lesions present in the genomic DNA (gDNA) of a cell could 
influence differences in potency of RhPPO, which targets these 
destabilized DNA features, in different cell lines.[5,7] Currently, 
there are few techniques developed for the detection and 
sensitive measurement of destabilized lesions in gDNA, such as 
polymerase chain reaction (PCR) amplification, but these 
techniques are destructive and time-consuming.[23] Fluorescence-
based probes have been widely used to visualize and quantify 
dynamic processes in live cells via interaction with various 
biological targets and are great candidates for screening of 
damaged DNA.[24]   
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Figure 3. A correlation between whole cell uptake and IC50 for RhPPO. A 
correlation of −0.63 is observed. MMR− cell lines are shown in red and MMR+ 
are shown in blue, with select cell lines labeled.  
 
As such, our group recently reported a bifunctional fluorescent 
probe, RhCy3, which exhibits a fluorescent light-up effect upon 
interaction with thermodynamically destabilized mismatches in 
gDNA (Figure 1).[25] The fluorescence of RhCy3 is an exceptional 
readout on the relative number of destabilized lesions in gDNA 
and an excellent predictor of the relative number of targetable 
DNA lesion for RhPPO, which is structurally similar.  
Here we use this probe to better understand the cytotoxic 
effect of RhPPO on a panel of cancer cell lines, but these studies 
also demonstrate the powerful detection and diagnostics 
properties of RhCy3 in MMR− cancers. We performed 
fluorescence titrations with RhCy3 and increasing amounts of 
gDNA extracted from a test set of eight cell lines that span 
deficiencies in different MMR genes (Table S2).[26] As can be seen 
in Figure 4, a correlation (r = -0.52) was observed between 
increasing RhCy3 fluorescence and decreasing IC50 of RhPPO. 
By removing the potential outlier, DU145 (the only cell line tested 
mutated in two MMR proteins), the correlation improves 
dramatically, (r = -0.81, p <0.05), suggesting other factors may 
influence the cytotoxicity of RhPPO or fluorescence of RhCy3 in 
DU145. This strong correlation between the IC50 of RhPPO and 
the fluorescence of the reporter RhCy3 confirms that the effective 
biological target of rhodium metalloinsertors is, in fact, DNA 
lesions such as mismatches and indels, and that differences in 
the number of these lesions between different cell lines controls 
cytotoxicity of metalloinsertor therapeutics. Notably, there is a 
clear relationship between the identity of MMR protein and RhCy3 
fluorescence output, showing RhCy3 can serve as a direct 
detection method of destabilized lesions in mismatch-repair 
deficient tumors and a potential diagnostic for these cancers 
(Supplemental Discussion and Figure S3).  
The results presented here highlight some interesting 
considerations for in vitro studies performed in any laboratory. We 
observed a large range of IC50 values spanning nearly three 
orders of magnitude for a single small molecule therapeutic 
across 27 cell lines. This result alone has significant implications 
for in vitro experiments. Many studies examine a therapeutic of 
interest in a single cell line or one cell line from several types of 
cancer (colorectal, ovarian, etc.), but a single cell line cannot 
represent cancer or any subtype of cancer as a whole. It is also 
common to compare cytotoxicity in unmatched cell lines that differ 
in the expression level of a protein of interest (regular expression, 
overexpression, and underexpression). Our results here suggest 
that using only a small number of unmatched cell lines may 
produce misleading results. For example, in this study we could 
consider MMR+ cells to have regular MMR expression and MMR− 
to underexpress MMR proteins. If we randomly chose only two 
cell lines from our panel, one MMR+ and one 
              
 
Figure 4. RhCy3 fluorescence assay with gDNA. Full fluorescence titrations of 
gDNA extracted from eight different cancer cell lines, with [gDNA] as per base 
pairs, I as the emission integral from 548 – 675 nm as scalar function measured 
after each addition of DNA, and I0 is the emission integral of RhCy3 solution 
without gDNA (top). Correlation of r = −0.52 is observed between IC50 value 
and max I/I0 for all cell lines (bottom). Removal of a potential outlier (circled) 
leads to correlation of r = −0.81 between IC50 value and max I/I0 for all cell lines. 
 
MMR−, we could observe every possible trend. Comparing RKO 
(MMR−, IC50: 120 nM) and Colo320DM (MMR+, IC50: 18.0 μM) 
would suggest RhPPO is dramatically more toxic in MMR− cells, 
however comparing CW2 (MMR−, IC50: 9.2 μM) and Colo205 
(MMR+, IC50: 63 nM) would suggest the opposite trend, with 
RhPPO being dramatically less toxic in MMR− cells. Overall, we 
believe the large range of IC50 values observed here serves as a 
point of caution for researchers performing in vitro studies in a 
limited number of cell lines. Cell line selection can unintentionally 
but dramatically influence the trends a researcher observes in 
their studies, therefore we encourage researchers to perform 
these studies with larger panels of cell lines and to supplement 
them using matched cell lines, which reduce the inter-cell line 
variation and allow one to observe the effect of a therapeutic on a 
specific target. 
In summary, the experiments described here underscore 
the therapeutic and diagnostic potentials of mismatch-targeting 
small molecules. The potency of RhPPO across diverse cell lines 
spans nearly three orders of magnitude and shows selectivity 
towards MMR-deficient cancer cells. RhPPO is on average 5 
times more potent than cisplatin, despite having a less abundant 
target to which it binds non-covalently. Overall, these results show 
RhPPO is a potent and promising therapeutic agent for colorectal 
cancers, and in vivo experiments involving mouse models are in 
progress. Significantly, the fluorescent probe RhCy3 provides 
-1.5 
-1 
-0.5 
0 
0.5 
1 
1.5 
0 3 6 9 12 
Lo
g 
(IC
50
) 
Uptake (ng Rh/mg protein) 
Colo205 
CW2 
DLD-1 
HCT15 
Ls123 
0 
1 
2 
3 
4 
5 
6 
7 
0 100 200 300 400 500 600 
I/I
0 
[gDNA] µM 
DU-145 
AN3-CA 
HCT116O 
HCT116 
DLD-1 
HEC-1A 
SW480 
HCT116N 
-1.5 
-1 
-0.5 
0 
0.5 
2.5 3.5 4.5 5.5 6.5 
Lo
g(
IC
50
)  
I/I0 at 600 µM gDNA  
10.1002/chem.201900042
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
COMMUNICATION          
 
 
 
 
clear evidence that destabilized DNA regions, such as 
mismatches, represent the cellular target for the metalloinsertors, 
and that targeting these lesions leads to cell death. As such, 
RhCy3 opens up great perspectives for development of new 
methods in direct detection and fast quantification of destabilized 
lesions in genomic DNA and as a fluorescent diagnostic tool for 
MMR deficient cancers.  
Experimental Section 
Materials. All commercially available reagents were used as received. The 
metalloinsertors [Rh(phen)(chrysi)(PPO)]Cl2 (RhPPO) and RhCy3 were 
synthesized and purified following published protocols.12,25 Cell culture 
media, supplements, and PureLink™ Genomic DNA Mini Kits were 
purchased from Life Technologies (Carlsbad, CA). CellTiter-Glo® 
Luminescent Cell Viability Assay kits were purchased from Promega 
(Madison, WI). BCA Protein Assay Kits were purchased from Pierce 
(Waltham, MA). Cell lines used in the experiment were purchased from 
ATCC (Manassas,VA) or provided by collaborators at AMGEN (Thousand 
Oaks, CA).  
Cell Culture. The specific growth conditions of each cell line, including the 
type of medium and added supplements, can be found in Table S1. In 
general, cell lines were grown in RPMI 1640, DMEM, McCoy’s 5A, or 
Ham’s F-12K media supplemented with 10% FBS (20% FBS for the cell 
line CaCo2), 100 units/mL penicillin, 100 units/mL streptomycin. Cells 
were grown in tissue culture treated flasks at 37 °C under a humidified 5% 
CO2 atmosphere.  
CellTiter-Glo Viability Assay. CellTiter-Glo Luminescent Cell Viability 
Assays were performed following the protocols provided in the kit. Briefly, 
cell lines were plated at a density of 10,000 cells in 100 μL media per well 
in an opaque, tissue culture treated 96-well plate and allowed to adhere 
for 24 h. One of two compounds, RhPPO or cisplatin, was added to each 
well at a final concentration of 0-150 μM, and the cells were allowed to 
incubate with the therapeutic for 72 h. After incubation with a therapeutic 
agent, the cell solutions were treated with an equal volume of the CellTiter 
Glo reagent, which contains beetle luciferin and a recombinant luciferase. 
The luciferase can catalyze a reaction between the luciferin and ATP 
provided by viable cells to produce a luminescence that is proportional to 
the number of viable cells. Luminescence was recorded on a FlexStation 
3 Multi-Mode Plate Reader with integration time of 0.500 seconds. Percent 
viability was determined by the ratio of the luminescence of therapeutic-
treated cells compared to untreated cells. IC50 values were determined by 
fitting the cell viability curve to a sigmoidal curve in OriginPro v 8.5 and 
using the resultant parameters to calculate the concentration at which 50% 
of cells were viable. Each therapeutic dose was performed in triplicate and 
each experiment was repeated 2-3 times to confirm reproducible viability 
curves. For statistical analyses, cell lines from a common patient (DLD-
1/HCT15, HT29/WiDr, SW480/SW620) were averaged and counted as a 
single cell line to avoid double-counting cancer from a single patient. 
ICP-MS Assay for Whole Cell Uptake of RhPPO. Whole cell uptake 
experiments were performed following previously published protocols with 
slight modifications.13 Briefly, cells were plated at a density of 1,000,000 
cells in 3 mL media per well in a 6-well plate and allowed to adhere for 24 
h. Cells were then treated with RhPPO to a final concentration of 0.5 μM. 
This concentration was selected to be great enough to ensure Rh detection 
by ICP-MS, but low enough to avoid significant cell death in sensitive cell 
lines (which could lead to challenges in data analysis). Cells were allowed 
to incubate for 24 h with the metalloinsertor, as we had previously 
observed that metalloinsertor uptake plateaus in both HCT116N and 
HCT116O cells by 24 h.13 For adherent cell lines, the rhodium-containing 
medium was aspirated from each well after 24 h and each well was 
washed 2x with 1 mL of phosphate-buffered saline (PBS) then harvested 
by trypsinization and transferred to centrifuge tubes. For mixed or 
suspended cell lines, the rhodium-containing medium was transferred to a 
centrifuge tube before the PBS rinses and trypsinization. Harvested cells 
were centrifuged at 1500 rpm for 5 minutes. The supernatant was 
decanted and the cell pellet was suspended in 1 mL PBS. Centrifugation 
and PBS washing was repeated three times total (for mixed/suspension 
cell lines, the suspended and trypsinized aliquots were combined during 
the second wash). An aliquot from the final suspension was reserved and 
analyzed for protein content using a Pierce BCA Protein Assay Kit 
following the manufacturers instructions. To lyse the cells and destroy 
membrane integrity, each cell suspension was sonicated for 20 s at 40% 
amplitude on a Qsonica Ultrasonic sonicator, then frozen and lyophilized 
for 72 h. The resulting cell particulate was suspending in 1 mL of 6% nitric 
acid and heated at 110 °C for 8 h to facilitate total digestion prior to ICP-
MS analysis. Each sample was then diluted to 2% nitric acid and 
centrifuged to separate any undigested cell components. The solutions 
were analyzed for Rh content on an Agilent 8800 Triple Quadrupole ICP-
MS. The concentration of Rh in each sample was determined by 
comparison to a standard curve ranging from 0.01 to 100 ppb. Rh 
concentrations were normalized to the protein content of each sample 
determined by BCA assay. The measurements were repeated two times 
using two biological replicates for each cancer cell line. 
Genomic DNA extraction and purification. The genomic DNA was 
extracted and purified using PureLink® Genomic DNA Kits following the 
manufacturer’s protocol. Prior to DNA extraction, the cells subjected to 
genomic DNA extraction were seeded and grown in their respective 
cellular medium at < 5 x 106 cells/mL. The lysates were prepared by 
removing the growth medium from the culture plate and cells were 
harvested by trypsinization then re-suspended in 200 μL PBS. 
ProteinaseK (20 μL) and RNase (20 μL) were added to the sample, mixed 
by vortexing and incubated at room temperature for 2 min. 200 μL of 
PureLink® Genomic Lysis/Binding Buffer were added, mixed and vortexed 
to obtain a homogenous solution. The samples were incubated at 55 °C 
for 10 min to promote digestion then 200 μL of 96-100% ethanol was 
added to the lysate which was further mixed by vortexing for 5 s. The DNA 
was washed by adding 500 μL of Wash Buffer 1 then Wash Buffer 2 
provided by the kit, followed by DNA eluting process using the spin 
columns. The spin columns were eluted with sterile MilliQ water (200μl) 
two times to recover a maximum of genomic DNA. The samples were 
lyophilized and the dry DNA was solubilized in Tris buffer solution (5 mM 
Tris, 50 mM NaCl, pH = 8.0) in order to obtain a highly concentrated 
solution. The concentration of gDNA solutions were determined using a 
NanoDrop 2000 Spectrophotometer (Thermo Scientific) by pippeting 2 μL 
of the sample solution. The samples purities were determined by obtaining 
the absorbance ratios at A260/A280 nm and A230/A260 nm using a 
NanoDrop 2000 Spectrophotometer and are reported in Table S3). The 
concentrations of the stock solutions of gDNA used during the 
fluorescence titrations were adjusted at 3140 ng/μl (4.7 mM base pairs 
DNA) in Tris buffer (200 mM NaCl, 5 mM Tris, pH 8.1). 
Fluorescence titrations with genomic DNA. Luminescence spectra 
were recorded using a QE Pro High Performance Spectrometer with a 
back-thinned, TE-cooled CCD detector controlled by the OceanView data 
acquisition and analysis software package (Ocean Optics, Inc.). Sample 
excitation was provided by a 455 nm LED (Thorlabs model M455L2). The 
fluorescence titrations in this study were performed with genomic DNA 
extracted from eight cancer cell lines characterized by different 
phenotypes (HCT116N, HCT116O, HCT116, DLD-1, HEC-1A, SW480, 
AN3-CA, DU-145). The emission spectra were recorded in Tris buffer 
solution (5 mM Tris, 200 mM NaCl, pH = 7.4) at 25 °C using a water 
circulation system. Excitation wavelength was λEx = 455 nm and emission 
integral was reported after each addition of genomic DNA, as a scalar 
function from 548 to 675 nm. The measurements were repeated three 
times using three biological replicates for each cancer cell line. 
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Targeting DNA Mismatches: Rhodium metalloinsertors are a versatile family of complexes that selectively bind to DNA mismatches in 
vitro. A range of cytotoxicities is found for the metalloinsertor with higher potency than cisplatin across a panel of colorectal cell lines, 
and we use a fluorescent analogue to confirm that the DNA mismatch is the primary biological target for the metalloinsertor in cells. 
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